Kornimate/medical-research-clean huggingface dataset:
intense pulsed light (ipl) medical device as treatment for patient suffering from skin disorder

Conditions: Excessive Hairiness; Vascular Lesion; Pigmented Lesions; Acne Vulgaris

Summary: the first ipl device obtained united states food and drug administration (fda) clearance in 1995 for treatment of lower extremity telangiectasias. since then, its favorable cost and versatility in contrast to many singlespectrum lasers, has led to its rapid proliferation and use in a number of different clinical settings. as described in the literature, anthélia medical device is intended to treat skin disorders: * excessive hairiness (hirsutism, hypertrichosis...) * vascular lesions (rosacea....) * pigmented lesions (lentigo et melasma) * acne vulgaris


Eligibility criteria:
inclusion criteria: * adult men or women * excessive hairiness: * patient with unwanted hair on the body (legs, arms, bikini line, or axilla) * patient over 18 years. * patients with fitzpatrick skin types from i to v. * women were required to be post-menopausal, surgically sterilized, or under a medically acceptable form of birth control (i.e., oral contraceptives, iud, contraceptive implant, or barrier methods with spermicide or abstinence) during the study time period. vascular lesions: * patients over 18 years. * patients with fitzpatrick skin types from i to iv. * patients with varicosities and rosacea on the face or upper and lower limbs. pigmented lesions: * patients over 18 years. * patients with solar lentigines on their cheeks, back, hands, arm and leg (\> 3 mm). * patient with fitzpatrick skin type from i to iv. acne: * patients over 18 years * patients with fitzpatrick skin types from i to iv. * patients with facial acne vulgaris on face. * willing to sun protect treated area for the duration of enrollment in the study and 4 weeks after treatment. exclusion criteria: * patients with history of malignant lesions or pre-malignant lesions, scarring, or infection in the area to be treated history of keloidal or hypertrophic scarring * patients with a known photosensitivity * pregnancy women * patient with diabetes mellitus suntan in the area to be treated * use of photo-sensitizing products for 7 days before treatment (selftanning lotions, activators, self-tanning shower gel, etc.) * exposure to the sun or uv rays at least 4 weeks before the treatment and 1 week afterwards * zones with uncovered tattoos, suspect spots or skin diseases (including spots, inflammation, beauty spots, tumors or melanomas, psoriasis, herpes...) * use of medication that induces anticoagulative medication or thromboembolic condition * patients with pacemaker or internal defibrillator * patients that used of nsaids two weeks prior to or 2 weeks following the treatment * epileptic patients * additional criteria for excessive hair: patients that use waxing or other methods of photo epilation within 1 month prior to treatment. * additional criteria for acne: patients currently under oral antibiotic or oral therapy for acne.
cognitive-behavioral bibliotherapy for the treatment of obsessive compulsive disorder in children and adolescents

Conditions: Obsessive-Compulsive Disorder

Summary: this 16-week program examines cognitive behavioral bibliotherapy to typical therapist-directed cognitive behavior therapy for children and adolescents with obsessive compulsive disorder.

this study is designed to compare self-directed bibliotherapy and therapist-directed cognitive behavioral therapy for children and adolescents with obsessive compulsive disorder (ocd). both treatments involve exposure and response prevention (ex/rp), in which the child confronts ocd fears and is asked to refrain from compulsive rituals (such as repetitive handwashing, counting, etc.). participants are requested to complete an initial evaluation to determine diagnosis, and four follow-up evaluations to assess symptom severity and change due to treatment for a total of 16 weeks. participant involvement to self-directed bibliotherapy versus traditional cognitive-behavioral treatment will be determined through random assignment. in the bibliotherapy condition, the child or adolescent will meet with a therapist twice over the course of treatment, along with a parent. the therapist will discuss a self-directed program of ex/rp to be implemented at a pace deemed appropriate by child and parent at their own home. the child and parent will be provided with a manual designed to instruct them how to cope with obsessive compulsive disorder. this treatment involves the parent and child reading the book, performing exercises, and monitoring symptoms on a weekly basis for 8 weeks. in the therapist-directed treatment condition, the child or adolescent will meet weekly with a therapist along with their parent. the therapist, parent, and child will work together to design and implement a program of ex/rp. this treatment involves performing exercises, monitoring symptoms on a weekly basis, and completing homework assignments. parents will be asked to help coach their child with at-home exercises challenging the obsessive compulsive disorder. this treatment lasts 12 weeks. evaluations will be conducted following the completion of each treatment to assess the efficacy of each treatment on ocd symptoms. the treatment and evaluations for ocd are provided free of charge.

Eligibility criteria:
inclusion criteria: * ages 8-18 years old * primary diagnosis of obsessive compulsive disorder * both parent and child fluent in english * parents must read at least a 7th grade reading level exclusion criteria: * primary psychiatric diagnosis other than ocd * current threat of harm to self or others * new use or dosage change of ocd medication 60 days prior to starting program * current involvement with another psychosocial therapy
to evaluate the pharmacokinetics (pk) and safety of tavapadon in participants with mild and moderate hepatic impairment compared to participants with normal hepatic function

Conditions: Hepatic Impairment

Summary: the primary purpose of the study is to assess the effect of hepatic impairment on the pk of tavapadon following administration of a single oral dose in participants with mild and moderate hepatic impairment relative to age, body weight, and sex-matched participants with normal hepatic function.


Eligibility criteria:
key inclusion criteria: 1. body mass index of ≥17.5 to 42.0 0 kilograms per meter square (kg/m\^2), inclusive, and a total body weight \>50 kilograms (kg) \[110 pounds (lbs)\]. 2. must meet the criteria for class a or b of the modified child-pugh classification. 3. stable hepatic disease defined as no clinically significant change in disease status in the last 28 days prior to the screening visit. 4. previous alcohol abuse is permitted provided that the participant is willing and able to follow lifestyle guidelines and has a negative breath alcohol test at screening and check-in (day -1). key exclusion criteria: 1. receipt of severe acute respiratory syndrome coronavirus 2 (sars-cov2) vaccine or booster within 7 days of planned dosing. 2. have recently been diagnosed with symptomatic coronavirus disease 2019 (covid-19) or test positive for covid-19 within 30 days prior to signing the informed consent form (icf). 3. taking any prohibited medication prior to randomization or likely to require prohibited concomitant therapy. 4. has received study drug in a clinical trial of tavapadon within 12 months of signing the icf. 5. acute hepatitis. 6. grade ≥2 hepatic encephalopathy. 7. participants who have received an organ transplant or are currently waiting for an organ transplant and are listed on the national transplant list. 8. primary biliary cholangitis or primary sclerosing cholangitis. note: other protocol-defined inclusion/exclusion criteria may apply.

Keywords: healthy volunteer mild hepatic impairment moderate hepatic impairment
oxidative stress and cardiovascular morbidity in sleep apnea-hypopnea syndrome (sahs)

Conditions: Sleep Apnea; Cardiovascular Diseases

Summary: the purpose of this study is to compare the levels of 8-isoprostane and other oxidative stress biomarkers in plasma and condensed exhaled air between patients with sahs and cardiovascular complications, patients with sahs without cardiovascular complications and control subjects. to evaluate the effect of three months of treatment with cpap on the oxidative stress biomarkers.

aim: to compare the levels of 8-isoprostane and other oxidative stress biomarkers in plasma and condensed exhaled air between patients with sahs and cardiovascular complications, patients with sahs without cardiovascular complications and control subjects. to evaluate the effect of three months of treatment with cpap on the oxidative stress biomarkers. design: randomized, double blind, of parallel groups and controlled with placebo study. study subjects: 53 patients with sahs (23 with cardiovascular complications and 30 without cardiovascular complications), 23 patients with cardiovascular diseases without sahs and 23 control subjects. interventions: three months of treatment with therapeutic cpap or with sham cpap (placebo). determinations: clinical (cardiovascular morbidity) and anthropometric data. fat free corporal mass, echocardiography, spirometry, ambulatory monitoring of the arterial pressure, endothelial reactivity. oxidative stress biomarkers (8-isoprostane, homocysteine, hif-1, nfkb, ap-1, vegf, et-1, tnf-alpha, il-1, il-6, icam-1, vcam-1, nitrates and nitrites) in plasma and condensed exhaled air.peripheral sensitivity to hypoxia. urinary excretion of catecholamines.

Eligibility criteria:
inclusion criteria: * sleep apnea-hypopnea syndrome (ahi \> 5) * excessive sleepiness (ess \> 11) * no previous cpap treatment exclusion criteria: * blood pressure \> 180/120 mmhg. * secondary hypertension * professional driver * copd, asthma, bronchiectasis, lung cancer, restrictive lung disorder, chest wall disease * neuromuscular disease or thyroid function abnormalities * morbid obesity (bmi \> 40 kg/m2). * respiratory infection in the 2 last months. * anemia (hb \ 55%). * diurnal hypercapnia (paco2 \> 45 mmhg) or moderate hypoxemia (pao2 \< 70 mmhg).

Keywords: sleep apnea morbidity cardiovascular cpap oxidative stress
magnesium sulphate versus lidocaine for control of emergence hypertension

Conditions: Craniotomy; Hypertension

Summary: post-craniotomy emergence hypertension is a common phenomenon that may predispose to development of intracranial hematoma and cerebral edema.the aim of this study is to compare the safety and efficacy of mgso4 versus lidocaine infusion for control of emergence hypertension after craniotomy.


Eligibility criteria:
inclusion criteria: * asa physical status ι or π. * scheduled patients for brain tumor excision. exclusion criteria: * hepatic, renal, cardiac, pulmonary, or endocrine impairment. * signs of increased intracranial pressure or allergy to any of the used drugs.

Keywords: craniotomy- emergence- hypertension
the effects of ∆-9-thc and naloxone in humans

Conditions: Healthy

Summary: the purpose of this project is to examine the effects of mu-opiate antagonism on the rewarding and reinforcing effects of delta-9-tetrahydrocannabinol (thc), the main psychoactive ingredient of cannabis.


Eligibility criteria:
inclusion criteria: * at least one exposure to cannabis exclusion criteria: * cannabis naive

Keywords: cannabis marijuana naloxone thc psychotic disorders
prevalence of respiratory aspiration in patients with copd

Conditions: COPD

Summary: the aim of the study is to estimate the prevalence of respiratory aspiration in patients with copd, in a tertiary hospital of buenos aires.

primary objective to estimate the prevalence of respiratory aspiration in patients with copd, in a tertiary hospital of buenos aires. secondary objective 1. to assess the association between the presence of aspiration and the usual degree of dyspnea in patients with copd. 2. to assess the association between the presence of aspiration and the amount of regular annual exacerbations in patients with copd. 3. to evaluate the association between the presence of aspiration and degree of severity according to gold criteria in patients with copd. 4. compare the estimated aspiration in copd patients with known prevalence of pulmonary aspiration in the general population in the same age patient prevalence patients will be recruited consecutively in the outpatient clinic of pulmonology and medical clinic, where a first encounter with the patient will be agreed. additionally, the investigators will cite patients identified as copd in the electronic medical records. during the first meeting the informed consent process to enter the protocol will take place, then the same baseline characteristics of the patient is taken into an online form. finally given a shift within 15 days after the first meeting for the feest, and if the patient did not have a spirometry over the past year to update a new turn. both studies will be conducted without any cost. in patients with impaired swallowing or aspiration presence is detected, we will inform the doctor to assess the need for additional studies. in turn, the patients will be referred to speech therapy services for rehabilitation of swallowing.

Eligibility criteria:
inclusion criteria - patients over 64 years diagnosed with chronic obstructive pulmonary disease guide gold criteria (fev1 / fvc ratio post bronchodilator \<0.70) exclusion criteria * refusal to participate or to process oral informed consent * contraindication for the feesst (history of vasovagal episodes, bilateral nasal obstruction, impaired homeostasis or frequent bleeding, dyskinesia, maxillofacial trauma or recent neck). * impaired understanding or cognition that hinder the consent or performing diagnostic tests required. * diagnosis of neurodegenerative disease associated with swallowing disorders known: parkinson, stroke with neurologic sequelae.

Keywords: copd respiratory aspiration copd acute exacerbation
dose-ranging study of sofosbuvir in combination with pegylated interferon and ribavirin in treatment naïve gt 1 hcv patients

Conditions: Hepatitis C

Summary: participants with genotype 1 hcv infection were randomized to 1 of 3 sofosbuvir doses (100 mg, 200 mg, or 400 mg) or matching placebo once daily based upon stratification for il28b status (cc or ct/tt). placebo tablets were administered to participants receiving 100 mg active sofosbuvir (3 placebo tablets) and 200 mg active sofosbuvir (2 placebo tablets) in order to maintain the study blind. participants received sofosbuvir/matching placebo from day 0 to 27. participants also received treatment with peg+rbv starting on day 0 of the study which continued for 48 weeks. participants were evaluated for sustained virologic response (svr) for an additional 24 weeks following completion of study treatment.


Eligibility criteria:
inclusion criteria: * treatment-naive males and females, 18-65 years of age * genotype 1 hcv infection * negative pregnancy test for females of childbearing age * females of childbearing age and males with female partners of childbearing age must use two forms of contraception during treatment and following the last dose of ribavirin in accordance with locally approved label for ribavirin exclusion criteria: * hepatitis b or hiv infection * pregnant or breast feeding females or male partners of pregnant females * previous interferon or ribavirin-based therapy or investigational anti-hcv agent * history or evidence of medical condition associated with chronic liver disease other than hcv

Keywords: chronic hepatitis c infection genotype 1 hcv gt1 gt 1
the characteristics of backscattering with depth in the progression of keratoconus

Conditions: Elasticum, Incomplete Pseudoxanthoma

Summary: to investigate the variation in backscattering with depth between forme fruste keratoconus (ffkc), keratoconus, and normal eyes; to determine the backscattering changes in the characteristics of keratoconus progression; and to explore the diagnostic value of backscattering in ffkc.

to investigate the variation in backscattering with depth between forme fruste keratoconus (ffkc), keratoconus, and normal eyes; to determine the backscattering changes in the characteristics of keratoconus progression; and to explore the diagnostic value of backscattering in ffkc. a scheimpflug corneal tomography image and caliper tool were used to obtain backscatter at every 2% depth at the thinnest point of the cornea, with the measured values expressed in grayscale units (gsu).

Eligibility criteria:
inclusion criteria: 1. bcva \<20/20 and a history of myopia or astigmatism; 2. presence of any of the following positive signs on slit lamp examination: corneal stromal thinning, cone-shaped anterior protrusions, fleischer's ring, vogt's striae, epithelial or subepithelial scarring; 3. abnormal corneal topography (maximum keratometry (k) value of \>47.2 diopters (d), bow-tie pattern with skewed radial axes, or inferior-superior asymmetry(3-mm i-s keratometric difference \>1.4 d). exclusion criteria: 1. patients with severe corneal scarring that affected light scattering and density maps showing "black holes" 2.participatients with other corneal diseases 3. eyes that have undergone surgery or trauma 4. eyes with corneal dystrophy -
comparison of intraoperative and postoperative outcomes of bartholin gland marsupialisation versus cystectomy

Conditions: Bartholin Abscess

Summary: to compare intraoperative and postoperative outcomes of bartholin marsupialisation versus excision

bartholin cysts and abscess are commonly seen. different surgical procedures are done for therapy. our aim is to compare intraoperative results and postoperative healing of patients undergoing marsupialisation versus excision.

Eligibility criteria:
inclusion criteria: * age 18-40, bartholin cyst/abscess exclusion criteria: * patients with systemical diseases, patients with recurrent bartholin abscess

Keywords: bartholin marsupialisation abscess
12-years follow-up on 166 female patients with fibromyalgia or chronic widespread pain

Conditions: Fibromyalgia; Chronic Widespread Pain

Summary: a 12-year follow-up of 166 women with fibromyalgia (fm) or chronic widespread pain (cwp) in western sweden. the 166 women participated in a randomised controlled trial called gau in 2004-2005, aiming to investigate the effect of pool exercise and patient education. the primary aim of the present study is to examine the change of symptoms after 11-12 years in 166 women with fm or cwp and also investigate predictors of change of symptoms and work ability. the 166 women will be asked to participate in the present follow-up study. the follow-up examination comprises a standardised interview of symptoms and demographic variables, a battery of self-administered questionnaires and tests of physical function.

a 12-year follow-up of 166 women with fibromyalgia (fm) or chronic widespread pain (cwp). the 166 women participated in a randomised controlled trial called gau 2004-2005 in three cities in western sweden; göteborg, alingsås and uddevalla. the rct aimed to investigate the effect of pool exercise and patient education. the primary aim of the present study is to examine the change of symptoms after 11-12 years in 166 women with fm or cwp and also investigate predictors of change of symptoms and work ability. the 166 women will be contacted by mail and telephone, and asked to participate in the present follow-up study. the follow-up examination comprises a standardised interview of symptoms and demographic variables, a battery of self-administered questionnaires and tests of physical function.

Eligibility criteria:
inclusion criteria of the present study gau-u: * all 166 patients who participated in the study gau in 2004/2005. (the inclusion criteria of gau was women with fm or cwp, 18-60 years old. patients with widespread pain; pain in the right and left side of the body, above and below the waist, as well as axial pain, for at least three months were classified as chronic widespread pain (cwp). patients who fulfilled the criteria for cwp and who also had pain at palpation of at least 11 of 18 pre-defined tender points were classified as fibromyalgia (fm). exclusion criteria for gau was serious physical or psychological disease) exclusion criteria of the present study gau-u: * patients who has developed serious physical or psychological disease since participating in the gau 2004/2005

Keywords: fibromyalgia chronic widespread pain follow-up pain fatigue symptoms workability physical function
digoxin evaluation in chronic heart failure: investigational study in outpatients in the netherlands

Conditions: Heart Failure

Summary: digoxin is the oldest, market-authorized drug for heart failure (hf), and very cheap. a large trial with digoxin, the dig trial, executed in the early nineties revealed a highly significant reduction in hf hospitalizations, but no effect on mortality. a post-hoc analysis of the dig trial suggests that low serum concentrations of digoxin may not only improve hf hospitalizations but also mortality in chronic hf patients. to confirm these retrospective analyses, a prospective, randomized, placebo-controlled trial is necessary to establish the position of digoxin in the contemporary treatment of hf. therefore, the investigators examine whether low-level, aiming for serum concentrations 0.5-0.9ng/ml, digoxin is beneficial in hf patients with reduced or mid-range ejection fractions (lvef \<50%).


Eligibility criteria:
inclusion criteria: 1. age ≥18year 2. outpatients with chronic hf, new york heart association \[nyha\] class ii - ambulatory iv 3. lvef\<50% 4. serum nt-probnp concentrations: previous hf hospitalization ≤ 1 year before randomisation ≥400pg/ml if sinus rhythm; ≥800pg/ml if af previous hf hospitalization \> 1 year before randomisation or in the absence of hf hospitalizations ≥ 600pg/ml if sinus rhythm; ≥1000 pg/ml if af bnp concentrations: previous hf hospitalization ≤ 1 year before randomisation ≥100pg/ml if sinus rhythm; ≥200pg/ml if af previous hf hospitalization \> 1 year before randomisation or in absence of hf hospitalization ≥150pg/ml if sinus rhythm; ≥250pg/ml if af. 5. ≥14 days stable on guideline-recommended therapy (doses and number of therapies as tolerated by each patient) exclusion criteria: 1. heart rate ≤60bpm (if sinus rhythm); heart rate ≤70bpm (if af) 2. history of hf hospitalization ≤7days 3. history of myocardial infarction, myocarditis, percutaneous intervention, rct, pacemaker/icd implantation, cardiac surgery or stroke ≤30 days 4. estimated glomerular filtration rate (egfr), ≤30ml/min/1.73m2 5. the presence of a mechanical assist device 6. use of inotropic drugs (dopamine, dobutamine, (nor)adrenaline, and milrinon) 7. scheduled for mechanical assist device or heart transplant 8. other non-cardiac conditions with limited life expectancy (≤ duration of the study) 9. amyloid, hypertrophic obstructive or constrictive cardiomyopathy 10. accessory atrio-ventricular pathway (e.g. wolf-parkinson-white syndrome) 11. (intermittent) complete heart block or second-degree av block type mobitz without pace maker or icd 12. severe (grade iii/iii) aortic valve disease 13. complex congenital heart disease 14. proven hypersensitivity to digoxin (prior side effects) 15. concomitant medication that interacts with digoxin 16. use of digoxin ≤6 months prior to inclusion 17. participation in another (intervention) clinical trial (registry studies not included) 18. women who are pregnant, breastfeeding or may be considering pregnancy during the study period

Keywords: heart failure digoxin atrial fibrillation